Natural Killer Cells Convergence Research Team - Stand Up to Cancer
Help save a life

This holiday season, Mastercard is standing with us in the fight to end cancer as we know it. From now until December 31st, 2018, if you use a Mastercard to donate to Stand Up To Cancer, Mastercard will TRIPLE your gift, up to $300,000!

That’s triple the impact to support groundbreaking cancer research that will help save lives now!

$25 = $75
$50 = $150
$100 = $300
$250 = $750
GIVE FOR LIFE
For every $1 donated through StandUpToCancer.org with a Mastercard, Mastercard will donate $2, up to $300,000. Offer starts 12/14/18 at 12:01am ET and ends 12/31/18 at 11:59pm ET, or at the $300,000 max, whichever comes first.

Convergence Teams

Research  >  Research Portfolio  >  Convergence Teams  >  Natural Killer Cells Convergence Research Team

SU2C Natural Killer Cells Convergence Research Team: Integrating Experimental and Computational Pipelines to Develop Biomarkers of Tumor Cell Resistance to NK Cells

Grant Term: January 2018–December 2020

This SU2C Natural Killer Cells Convergence Research Team is conducting an in-depth study of natural killer (NK) cells and their anticancer properties using a CRISPR screen, sophisticated bioinformatics, and high-tech culture techniques. The team is engaging computational teams with follow-up in a clinical setting to model bone marrow living tissue scaffolds with humanized stromal tissue.

ABOUT THIS TEAM’S RESEARCH

Natural killer (NK) cells, white blood cells that play a role in viral response, have potent antitumor properties. Moreover, NK cells are not inhibited by many of the strategies cancer cells use to evade the immune system. This SU2C Natural Killer Cells Convergence Research Team hypothesizes that the genetic makeup of a tumor may serve as a basis for targeting its destruction by NK cells.

To identify biomarkers that indicate tumor cell sensitivity or resistance to NK cells, the team is using computational approaches. Team members are also exploring novel ways in which NK cells affect tumor cells by using tools such as CRISPR screens. They are also validating these biomarkers on different experimental platforms, such as patient-derived organoids and high-throughput systems to quantify tumor cell responses to immune effector cells.

Results from this research could impact models used to develop therapies for a wide range of cancers.

MEET THE TEAM

The top scientists and researchers on the SU2C Natural Killer Cells Convergence Research Team come from a variety of backgrounds and disciplines, which leads them to great insights upon collaboration. Learn more about the SU2C Natural Killer Cells Convergence Research Team.

Team Members

Constantine Mitsiades, MD, PhD
Dana-Farber Cancer Institute
Team Leader

Aedin Culhane, PhD
Dana-Farber Cancer Institute
Team Member

Todd Golub, MD
Broad Institute of MIT and Harvard
Team Member

Jennifer Roth, MSc, MBA
Broad Institute of MIT and Harvard
Team Member

Michal Sheffer, PhD
Dana-Farber Cancer Institute
Team Member

Ricardo de Matos Simoes, PhD
Dana-Farber Cancer Institute
Team Member

Aviad Tsherniak, MSc
Broad Institute of MIT and Harvard
Team Member

Alice Lustig
Stand Up To Cancer
Project Manager

TEAM PROGRESS UPDATES

Stand Up To Cancer’s research projects are designed to foster collaborative, swift translational research. The hallmarks of these efforts include rigorous application and selection procedures, sufficient funding to allow scientists to focus on the objectives of the grant, and six-monthly reviews by senior scientists. These reviews help the investigators capitalize on the latest findings, address potential roadblocks, and collaboratively evolve as the science requires. Please click on the link to see summaries of research results so far for the SU2C Natural Killer Cells Convergence Research Team.

TEAM PROGRESS UPDATES

PUBLICATIONS

This team started its work in January 2018. Links to publications will be posted when they are available.

CLINICAL TRIALS REFERRALS

Cancer clinical trials allow researchers to study innovative and potentially life-saving new treatments. The goal is to find treatments that are better than what’s currently available; in fact, the therapies offered to today’s cancer patients were almost all studied and made possible by people participating in clinical trials. But many cancer clinical trials aren’t completed because not enough people take part.

At StandUpToCancer.org/ClinicalTrials, you’ll find information and answers to common questions about clinical trials. Learn more and talk to your doctor to see if a clinical trial may be the best choice for you.

You can also connect with EmergingMed, a free and confidential clinical trial matching service that provides access to a vast database to help you identify the clinical trials that might be right for you or your loved one.

LEARN MORE